Current Report Filing (8-k)
September 06 2022 - 9:11AM
Edgar (US Regulatory)
0001513525
false
0001513525
2022-09-06
2022-09-06
0001513525
us-gaap:CommonStockMember
2022-09-06
2022-09-06
0001513525
ADIL:WarrantsMember
2022-09-06
2022-09-06
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (date of earliest event reported):
September 6, 2022
Adial Pharmaceuticals, Inc.
(Exact name of registrant as specified in charter)
Delaware
(State or other jurisdiction of incorporation)
001-38323 |
|
82-3074668 |
(Commission File Number) |
|
(IRS Employer
Identification No.) |
1180 Seminole
Trail, Suite 495
Charlottesville, Virginia 22901
(Address of principal executive offices and
zip code)
(434) 422-9800
(Registrant’s telephone number including
area code)
(Former Name and Former Address)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:
☐ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting
material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbols |
|
Name of each exchange on which registered |
Common Stock |
|
ADIL |
|
NASDAQ |
Warrants |
|
ADILW |
|
NASDAQ |
Indicate by check mark whether the registrant
is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by checkmark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
Item 7.01. Regulation
FD Disclosure.
On September 6, 2022,
Adial Pharmaceuticals, Inc. (the “Company”) issued a press release announcing in-vivo non-clinical data with Purnovate’s
PNV-6005 as a potential treatment for ulcerative colitis and other inflammatory bowel diseases.
The information in this
Item 7.01 and in the press release furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section
or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended and shall not be incorporated by reference into any filing with
the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general
incorporation language in such filing.
The press release furnished
as Exhibit 99.1 to this Current Report on Form 8-K includes “safe harbor” language pursuant to the Private Securities Litigation
Reform Act of 1995, as amended, indicating that certain statements contained therein are “forward-looking” rather than historical.
Item 8.01. Other
Events.
On September 6, 2022, the Company issued a press
release announcing in-vivo non-clinical data with Purnovate’s PNV-6005 as a potential treatment for ulcerative colitis and other
inflammatory bowel diseases. In the study, PNV-6005 demonstrated statistically significant effect against both primary study endpoints,
which are pre-clinical endpoints expected to indicate potential efficacy against ulcerative colitis in humans. Specially, PNV-6005 (i)
significantly prevented weight loss as compared to the control group (greater than 50% inhibition of weight loss) and (ii) significantly
prevented colon damage as evidenced by reduction of shortening of colon lengths in the PNV-6005 treated group (almost total prevention),
as well as a decrease in inflammation as assessed histologically.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: September 6, 2022 |
ADIAL PHARMACEUTICALS, INC. |
|
|
|
By: |
/s/ Cary J. Claiborne |
|
Name: |
Cary J. Claiborne |
|
Title: |
President and Chief Executive Officer |
Adial Pharmaceuticals (NASDAQ:ADIL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Adial Pharmaceuticals (NASDAQ:ADIL)
Historical Stock Chart
From Jul 2023 to Jul 2024